OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma

January 12th 2022

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.

Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL

January 12th 2022

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Bekaii-Saab on the Promise of Non–VEGF Inhibitor Platforms in HCC

January 12th 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the promise of non–VEGF inhibitor platforms in hepatocellular carcinoma.

Dr. Zurita-Saavedra on Augmenting Therapy Earlier in Prostate Cancer Treatment Journey

January 11th 2022

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Dr. Verstovsek on the Goal of the IMPactMF Trial With Imetelstat in Myelofibrosis

January 11th 2022

Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.

Dr. Morris on Logistical Challenges of Using 177Lu-PSMA-617 in Prostate Cancer

January 11th 2022

Michael J. Morris, MD, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate cancer.

Dr. Rimawi on the Promise of the HER2CLIMB-02 Trial in HER2+ Breast Cancer

January 11th 2022

Mothaffar Fahed Rimawi, MD, discusses the promise of the phase 3 HER2CLIMB-02 trial in HER2-positive metastatic breast cancer.

Dr. Anders on the Lessons Learned From the OlympiA Trial in BRCA-Mutated Breast Cancer

January 11th 2022

Carey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Dr. Riedell on Unique Data Points from an Analysis in MCL

January 11th 2022

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

Dr. Mulcahy on the Design of the EPOCH Trial in mCRC With Liver Metastases

January 11th 2022

Mary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.

Dr. Iams on Establishing the Clinical Utility of ctDNA Testing in Lung Cancer

January 10th 2022

Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.

Dr. Phillips on Considering Age During Treatment Selection With BTK Inhibitors in MCL

January 10th 2022

Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.

Dr. Spaggiari on Considerations for Patients With CRC and Liver Metastases Without Surgical Options

January 10th 2022

Mario Spaggiari, MD, discusses considerations for patients with colorectal cancer and liver metastases who have no surgical options.

Dr. Feldman on Adding Etoposide to Brentuximab Vedotin/CHP in Peripheral T-Cell Lymphomas

January 10th 2022

Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.

Dr. Goy on the Utility of Axi-Cel and Brexu-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

January 10th 2022

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Sallman on the Responses to PRGN-3006 in Select AML and Higher-Risk MDS

January 10th 2022

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

Dr. Seymour on the Safety of Acalabrutinib Vs Ibrutinib in Relapsed/Refractory CLL

January 10th 2022

John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPC

January 10th 2022

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Dr. McCloskey on the Utility of Decitabine Plus Cedazuridine in Lower-Risk MDS

January 7th 2022

James K. McCloskey, MD, discusses the utility of decitabine plus cedazuridine in lower-risk myelodysplastic syndromes, based on data from the long-term follow-up of the phase 3 ASCERTAIN trial.

Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

January 7th 2022

Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.